Horizon Therapeutics PLC (NASDAQ:HZNP) – Analysts at Jefferies Financial Group upped their FY2020 earnings per share estimates for shares of Horizon Therapeutics in a research note issued to investors on Tuesday, January 21st. Jefferies Financial Group analyst D. Steinberg now anticipates that the biopharmaceutical company will post earnings of $1.95 per share for the year, up from their previous estimate of $1.93. Jefferies Financial Group currently has a “Buy” rating and a $40.00 target price on the stock.
Horizon Therapeutics (NASDAQ:HZNP) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.14. Horizon Therapeutics had a net margin of 5.25% and a return on equity of 27.71%. The firm had revenue of $335.50 million during the quarter, compared to the consensus estimate of $330.60 million. During the same quarter last year, the firm earned $0.65 EPS. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year.
HZNP stock traded up $0.13 during trading on Friday, hitting $37.24. 80,902 shares of the company’s stock traded hands, compared to its average volume of 1,367,215. The firm has a market capitalization of $7.22 billion, a P/E ratio of 100.65, a PEG ratio of 1.64 and a beta of 0.89. Horizon Therapeutics has a 1 year low of $20.05 and a 1 year high of $39.10. The company has a quick ratio of 2.23, a current ratio of 2.33 and a debt-to-equity ratio of 0.87. The business has a fifty day simple moving average of $35.76 and a two-hundred day simple moving average of $29.46.
In related news, EVP Brian K. Beeler sold 12,475 shares of Horizon Therapeutics stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $30.02, for a total value of $374,499.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Brian K. Beeler sold 6,716 shares of Horizon Therapeutics stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $35.00, for a total transaction of $235,060.00. Following the completion of the sale, the executive vice president now owns 77,917 shares of the company’s stock, valued at approximately $2,727,095. The disclosure for this sale can be found here. In the last three months, insiders have sold 126,888 shares of company stock valued at $4,413,598. 4.10% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of HZNP. AMI Asset Management Corp acquired a new stake in shares of Horizon Therapeutics in the fourth quarter valued at $11,317,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Horizon Therapeutics by 21.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,016 shares of the biopharmaceutical company’s stock valued at $507,000 after acquiring an additional 2,519 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Horizon Therapeutics during the fourth quarter valued at approximately $2,383,000. Nisa Investment Advisors LLC increased its position in shares of Horizon Therapeutics by 1.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 21,060 shares of the biopharmaceutical company’s stock valued at $762,000 after acquiring an additional 300 shares during the last quarter. Finally, Mirador Capital Partners LP purchased a new stake in Horizon Therapeutics in the fourth quarter worth $596,000. Institutional investors and hedge funds own 88.23% of the company’s stock.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Article: Roth IRA
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.